• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

byNeel MistryandTeddy Guo
March 15, 2022
in Chronic Disease, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There was no evidence of superiority among the different antipsychotics.

2. Choice of antipsychotic regimen for schizophrenia maintenance should be guided by side effect profiles.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Schizophrenia is a common, chronic, and debilitating psychiatric condition. While antipsychotics are often used as first-line treatment for patients with schizophrenia, they are often associated with notable adverse effects. This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the safety and efficacy of 32 oral and long-acting injectable antipsychotics for maintenance treatment of adults with schizophrenia. The primary outcome was the proportion of patients with symptom relapse, while key secondary outcomes included patients readmitted to hospital, those in remission, and those discharged. According to study results, most antipsychotics had a lower risk of relapse compared to placebo. However, there was no major difference in efficacy between the types of antipsychotics. Significant differences in side effects such as weight gain, sedation, Parkinsonism, and QTc interval prolongation were noted and varied depending on the antipsychotic. This study was strengthened by the inclusion of a broad array of antipsychotics; however, it did not compare the effect of route of administration (long-acting injectable vs. oral) on symptom relapse.

Click to read the study in The Lancet

Relevant Reading: A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

In-depth [systematic review and meta-analysis]: An initial search of Cochrane and PubMed obtained 4157 references. Included were randomized controlled trials (RCTs) assessing the effect of antipsychotics on adults with stable schizophrenia or schizoaffective disorder, while articles showing resistance to antipsychotics were excluded. In total, 501 references (comprising 127 RCTs with 18 152 patients) were included in the analysis. The primary outcome of symptom relapse was lower in the antipsychotic group (risk ratio [RR] < 1.00) compared to placebo. With respect to symptom relapse, zuclopenthixol LAI (RR 0.07, 95% credible interval [CrI] 0.00-0.34) and paliperidone PO (RR 0.20, 95% CrI 0.05-0.41) were most effective, while lurasidone PO (RR 0.63, 95% CrI 0.25-1.02) and cariprazine PO (0.65, 0.16-1.14) were least effective. There was no evidence of superiority among the various antipsychotics. Overall, findings from this study suggest that use of antipsychotic is superior to placebo for management of schizophrenia. However, given that there is no consensus on which antipsychotic is most effective, its use should be guided mainly by patient tolerance to side effects.

RELATED REPORTS

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

Physical activity may be helpful in treating depressive symptoms in children and adolescents

ECT may be more effective than ketamine in improving depression severity

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Antipsychoticantipsychotic medicationsHaloperidolmental healthOlanzapinepsychiatryPsychosisquetiapinerisperidoneschizophrenia
Previous Post

Maternal substance use may increase risk of childhood Attention Deficit Hyperactivity Disorder

Next Post

Early intervention services for children exposed to lead associated with improved standardized test performance

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Fight Against Childhood Obesity, Prioritizing Mental Health, The Rise of XBB1.5, and Choose Your Chocolates Wisely

January 25, 2023
Certain financial incentive programs may promote increased physical activity
Chronic Disease

Physical activity may be helpful in treating depressive symptoms in children and adolescents

January 18, 2023
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Psychiatry

ECT may be more effective than ketamine in improving depression severity

January 18, 2023
2 Minute Medicine Rewind October 21, 2019
Psychiatry

Several factors impede the successful implementation of youth mental health apps

January 17, 2023
Next Post
Meeting families, demographic information affect child abuse work-up

Early intervention services for children exposed to lead associated with improved standardized test performance

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Effectiveness of Covid-19 vaccines waned over timer in North Carolina

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gender-affirming hormones improve psychosocial functioning in transgender youth
  • Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients
  • #VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options